Join
Live feed
·
PRReleasevia Quantisnow
Spero Therapeutics Inc. logo

Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

ByQuantisnow·Wall Street's wire, on your screen.
SPRO· Spero Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SPRO (Spero Therapeutics Inc.) and more on Quantisnow.